quetiapine has been researched along with clozapine in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (8.33) | 18.2507 |
| 2000's | 11 (45.83) | 29.6817 |
| 2010's | 10 (41.67) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| De Loore, K; Gommeren, W; Janssen, PF; Lesage, AS; Leysen, JE; Luyten, WH; Schotte, A; Van Gompel, P | 1 |
| Audinot, V; Chaput, C; Conte, C; Gavaudan, S; Millan, MJ; Newman-Tancredi, A; Touzard, M; Verrièle, L | 1 |
| Bristow, LJ; Hutson, PH; Rowley, M | 1 |
| Klitgaard, H; Matagne, A; Talaga, P | 1 |
| Gatos, GC; Kirkland, KM; McLaren, FM; Migler, BM; Needles, AL; Nelson, CL; Ohnmacht, CJ; Warawa, EJ | 1 |
| Boulton, DW; DeVane, CL; Liston, HL; Markowitz, JS | 1 |
| Ernsberger, P; Hufeisen, SJ; Jayathilake, K; Kroeze, WK; Meltzer, HY; Popadak, BA; Renock, SM; Roth, BL; Steinberg, S | 1 |
| Wermuth, CG | 1 |
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Huang, AS; Kim, SF; Snowman, AM; Snyder, SH; Teuscher, C | 1 |
| Coolen, HK; Glennon, JC; Kruse, CG; Lange, JH; Reinders, JH; Tolboom, JT | 1 |
| Ablordeppey, SY; Altundas, R; Bricker, B; Jackson, T; Khan, A; Kumar, EV; Roth, BL; Zhu, XY | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Sen, S; Sinha, N | 1 |
| Bartolome, JM; Langlois, X; Macdonald, GJ; Tresadern, G | 1 |
| Andres-Mach, M; Czuczwar, S; Dawidowski, M; Herold, F; Kleps, J; Mazurek, A; Mazurek, AP; Nowak, G; Pluciński, F; Stachowicz, K; Stefanowicz, J; Szewczyk, B; Sławińska, A; Słowiński, T; Wolska, I; Łuszczki, JJ | 1 |
| Deville, M; Dilly, S; Lamy, C; Liégeois, JF; Mangin, F; Résimont, M; Tarazi, FI | 1 |
| Dalvie, D; Loi, CM; Smith, DA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Andres-Mach, M; Bączek, T; Belka, M; Czuczwar, SJ; Gomółka, AE; Herold, F; Jastrzębska-Więsek, M; Nowak, G; Partyka, A; Siwek, A; Stefanowicz, J; Słowiński, T; Turło, J; Ulenberg, S; Wesołowska, A; Wróbel, MZ; Zagaja, M; Żołnierek, M; Łuszczki, JJ | 1 |
| Azmanova, M; Barry, NPE; Pitto-Barry, A | 1 |
| Freeman, BB; Rankovic, Z; Yang, L | 1 |
| Horiguchi, M; Ishida, K; Isobe, Y; Nakako, T; Watanabe, H; Yamamoto, M | 1 |
5 review(s) available for quetiapine and clozapine
| Article | Year |
|---|---|
Current and novel approaches to the drug treatment of schizophrenia.
Topics: Animals; Antipsychotic Agents; Cholinergic Agonists; Disease Models, Animal; Dopamine Antagonists; Enzyme Inhibitors; Excitatory Amino Acid Antagonists; Humans; Mice; Mice, Transgenic; Nitric Oxide Synthase; Receptor, Serotonin, 5-HT2A; Receptors, AMPA; Receptors, Dopamine D2; Receptors, Dopamine D4; Receptors, Metabotropic Glutamate; Receptors, N-Methyl-D-Aspartate; Receptors, Neurotensin; Receptors, Serotonin; Schizophrenia; Serotonin Antagonists | 2001 |
Selective optimization of side activities: another way for drug discovery.
Topics: Animals; Biological Availability; Combinatorial Chemistry Techniques; Databases, Factual; Drug Design; Humans; Patents as Topic; Pharmaceutical Preparations; Structure-Activity Relationship | 2004 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Schizophrenia: synthetic strategies and recent advances in drug design.
Topics: | 2018 |
Practical approaches to evaluating and optimizing brain exposure in early drug discovery.
Topics: Animals; Blood-Brain Barrier; Central Nervous System; Central Nervous System Agents; Drug Delivery Systems; Drug Discovery; Humans; Molecular Structure; Structure-Activity Relationship | 2019 |
19 other study(ies) available for quetiapine and clozapine
| Article | Year |
|---|---|
Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.
Topics: Animals; Antipsychotic Agents; Brain; Cells, Cultured; Clozapine; Haloperidol; Humans; Male; Rats; Rats, Wistar; Receptors, Dopamine; Receptors, Serotonin; Risperidone | 1996 |
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.
Topics: Animals; Antipsychotic Agents; CHO Cells; Cricetinae; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Serotonin Agents; Sulfur Radioisotopes | 1998 |
Pharmacological evaluation of a diarylmethylene-piperidine derivative: a new potent atypical antipsychotic?
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Mice; Piperidines; Protein Binding; Psychomotor Agitation; Psychotic Disorders; Receptors, Dopamine D2; Receptors, Serotonin; Serotonin Antagonists | 2001 |
Behavioral approach to nondyskinetic dopamine antagonists: identification of seroquel.
Topics: Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Cebus; Dibenzothiazepines; Dopamine Antagonists; Dyskinesia, Drug-Induced; Female; Male; Mice; Quetiapine Fumarate; Receptors, Dopamine D2; Stereoisomerism; Structure-Activity Relationship | 2001 |
In vitro P-glycoprotein affinity for atypical and conventional antipsychotics.
Topics: Antipsychotic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzodiazepines; Binding, Competitive; Clozapine; Dibenzothiazepines; Dose-Response Relationship, Drug; Humans; Kinetics; Olanzapine; Pirenzepine; Quetiapine Fumarate; Recombinant Proteins; Risperidone | 2002 |
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; Discriminant Analysis; Drug Evaluation, Preclinical; Forecasting; Humans; Protein Binding; Receptors, Histamine H1; Statistics, Nonparametric; Weight Gain | 2003 |
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase.
Topics: Adenylate Kinase; Animals; Antipsychotic Agents; Enzyme Activation; Hypothalamus; Immunohistochemistry; Mice; Phosphorylation; Receptors, Histamine H1; Weight Gain | 2007 |
Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzoxazines; Biogenic Monoamines; Humans; Hyperprolactinemia; Indoles; Metabolic Diseases; Phthalimides; Piperazines; Principal Component Analysis; Pyridines; Radioligand Assay; Receptors, Biogenic Amine; Weight Gain | 2007 |
Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.
Topics: Animals; Antipsychotic Agents; Apomorphine; Azepines; Butyrophenones; Clozapine; Haloperidol; Lethal Dose 50; Male; Mice; Molecular Structure; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Structure-Activity Relationship | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Molecular properties affecting fast dissociation from the D2 receptor.
Topics: Antipsychotic Agents; Dopamine D2 Receptor Antagonists; Drug Administration Schedule; Drug Design; Humans; Molecular Structure; Receptors, Dopamine D2; Structure-Activity Relationship | 2011 |
Synthesis and biological investigation of potential atypical antipsychotics with a tropane core. Part 1.
Topics: Animals; Antipsychotic Agents; Dose-Response Relationship, Drug; Mice; Models, Molecular; Radioligand Assay; Rats; Receptors, Neurotransmitter; Structure-Activity Relationship; Tropanes | 2011 |
New pyridobenzoxazepine derivatives derived from 5-(4-methylpiperazin-1-yl)-8-chloro-pyrido[2,3-b][1,5]benzoxazepine (JL13): chemical synthesis and pharmacological evaluation.
Topics: Animals; Antipsychotic Agents; Brain; CHO Cells; Cricetinae; Cricetulus; Humans; In Vitro Techniques; Male; Models, Molecular; Organ Specificity; Oxazepines; Piperazines; Pyridines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptors, Adrenergic, alpha-2; Receptors, Dopamine D2; Receptors, Dopamine D4; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT1 Receptor Antagonists; Structure-Activity Relationship | 2012 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
Synthesis and biological investigation of new equatorial (β) stereoisomers of 3-aminotropane arylamides with atypical antipsychotic profile.
Topics: Animals; Antipsychotic Agents; Benzene Derivatives; Dopamine D2 Receptor Antagonists; Male; Mice; Rats, Wistar; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Serotonin 5-HT2 Receptor Antagonists; Stereoisomerism; Structure-Activity Relationship; Tropanes | 2016 |
Identification of 2-fluoro-8-methyl-11-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-5H-dibenzo[b,e][1,4]diazepine with clozapine-like mixed activities at muscarinic acetylcholine, dopamine, and serotonin receptors.
Topics: Acetylcholine; Animals; Antipsychotic Agents; Azepines; Cholinergic Agents; Clozapine; Dopamine; Drug Evaluation, Preclinical; Humans; Mice; Olanzapine; Protein Binding; Quetiapine Fumarate; Receptors, Cholinergic; Receptors, Dopamine; Receptors, Serotonin; Small Molecule Libraries; Structure-Activity Relationship | 2021 |